BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteria NEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update. "Our main priority continues to be advancing NurOwn into a Phase 3b confirmatory study, having received clearance from the FDA in 2025 for the planned study," said Chaim Lebovits, President and CEO.